News & Updates

Patients with chronic hepatitis B (CHB) still have a non-negligible risk of hepatocellular carcinoma (HCC) 12 years after achieving hepatitis B surface antigen (HBsAg) seroclearance, especially if cirrhosis is present, a large territory-wide real-world study in Hong Kong has shown.

Use of telbivudine (LdT) during the second trimester of pregnancy helps prevent mother-to-child transmission of hepatitis B virus, reveals a study. In addition, treatment with LdT during pregnancy is safe in the long term for both mothers and infants.

Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.

Longitudinal changes in fibrosis-4 (FIB-4) score are strongly predictive of progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD), reveals a study.

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

Researchers from the University of Hong Kong (HKU) have developed a nanoparticle-based targeted drug delivery system that selectively transports thyroid hormone (TH) to adipose tissue, which may improve treatment of obesity and its related cardiometabolic complications by overcoming serious adverse events (AEs) associated with systematic TH administration.

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.